Many Alzheimer's patients would not have been eligible for clinical trials of controversial new drug
In June 2021, the Food & Drug Administration (FDA) granted accelerated approval for aducanumab to treat patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The two phase-3 clinical trials ...
Sep 9, 2021
0
3